The Fate of Porous Hydroxyapatite Granules Used in Facial Skeletal Augmentation

Facial appearance is largely determined by the morphology of the underlying skeleton. Hydroxyapatite is one of several materials available to enhance projection of the facial skeleton. This study evaluated the long-term maintenance of augmented bony projection when porous hydroxyapatite granules are used on the facial skeleton. Ten female patients aged 28–58 years were studied following aesthetic augmentation of the facial skeleton at 24 sites using porous hydroxyapatite granules. Postoperative CT scans at 3 months served as the baseline measurement and compared with scans taken at 1 and 2 years, with the thickness of the hydroxyapatite measured in axial and coronal planes. Thickness of original bone plus overlay of hydroxyapatite, thickness of the overlying soft tissue, and the overall projection (bone plus soft tissue) were recorded. It was found that 99.7% of the hydroxyapatite was maintained at 2 years, with no statistical difference (t test) from the baseline measurement. The overall projection (bony and soft tissue) was maintained as there was no evidence of native bone resorption or soft tissue atrophy. Radiographic results confirmed that the use of porous hydroxyapatite granules for enhancement of the facial skeleton is not only a predictable procedure, but maintains full bony projection at 2 years

ArteFill® Permanent Injectable for Soft Tissue Augmentation: II. Indications and Applications

Patients ask for procedures with long-lasting effects. ArteFill is the first permanent injectable approved in 2006 by the FDA for nasolabial folds. It consists of cleaned microspheres of polymethylmethacrylate (PMMA) suspended in bovine collagen. Over the development period of 20 years most of its side effects have been eliminated to achieve the same safety standard as today’s hyaluronic acid products. A 5-year follow-up study in U.S. clinical trial patients has shown the same wrinkle improvement as seen at 6 months. Long-term follow-up in European Artecoll patients has shown successful wrinkle correction lasting up to 15 years. A wide variety of off-label indications and applications have been developed that help the physician meet the individual needs of his/her patients. Serious complications after ArteFill injections, such as granuloma formation, have not been reported due to the reduction of PMMA microspheres smaller than 20 μm to less than 1% “by the number.” Minor technique-related side effects, however, may occur during the initial learning curve. Patient and physician satisfaction with ArteFill has been shown to be greater than 90%

Frontal Bone Remodeling for Gender Reassignment of the Male Forehead: A Gender-Reassignment Surgery

Gender-reassignment therapy, especially for reshaping of the forehead, can be an effective treatment to improve self-esteem. Contouring of the cranial vault, especially of the forehead, still is a rarely performed surgical procedure for gender reassignment. In addition to surgical bone remodeling, several materials have been used for remodeling and refinement of the frontal bone. But due to shortcomings of autogenous bone material and the disadvantages of polyethylene or methylmethacrylate, hydroxyapatite cement (HAC) composed of tetracalcium phosphate and dicalcium phosphate seems to be an alternative. This study aimed to analyze the clinical outcome after frontal bone remodeling with HAC for gender male-to-female reassignment. The 21 patients in the study were treated for gender reassignment of the male frontal bone using HAC. The average age of these patients was 33.4 years (range, 21–42 years). The average volume of HAC used per patient was 3.83 g. The authors’ clinical series demonstrated a satisfactory result. The surgery was easy to perform, and HAC was easy to apply and shape to suit individual needs. Overall satisfaction was very high. Therefore, HAC is a welcome alternative to the traditional use of autogenous bone graft for correction of cranial vault irregularities

Orbital floor fractures - aspects of diagnostic methods, treatment and sequelae

Despite surgical intervention, orbital floor fractures are associated with risks of persisting sensibility disturbances, enophthalmos and diplopia. Cheek asymmetry and trismus may result when the zygoma is dislocated. In evaluating the surgical results patients’ experiences of the outcomes have to be investigated. To investigate sequelae a questionnaire was sent to 107 patients previously treated for an orbital floor fracture (Paper I). Visual analogue scales (VASs) were used in a prospective study (Papers II and III) to assess patients’ experiences of persisting signs and symptoms. The possibility of using electronystagmography (ENG) equipment, normally employed in vestibular testing in ENT practice, for measuring bilateral vertical eye motility was investigated in a methodological study (Paper IV). Fractures were mainly due to assaults and falls. Sequelae were common (83%). A high frequency of diplopia (36%) was associated with antral packing. When stable floor implants replaced this technique, the subsequent prospective study revealed absence of severe cases of diplopia as well as a lower occurrence of diplopia (9.5%). Patients and doctors agreed on the presence of ‘objective’ signs (affected physical appearance and diplopia). Sensibility disturbances and reduced mouth opening capacity were not sufficiently reflected by the diagnostic assessment methods used, and these symptoms were underestimated by the clinicians. Surgery of the internal orbit involves risks. For this reason, operations for purely diagnostic purposes must be avoided. However, 21% of the orbital floor operations in the present study were performed for purely diagnostic purposes. Surgeons did not apprehend the CT scans as being representative of the fracture. No test is at present available that can objectively establish entrapment of soft tissues as a cause of diplopia, although this is an absolute indication for surgery. However, vertical electro-oculography (vEOG) was shown to (i) objectively measure vertical eye motility; (ii) detect and verify mechanical restriction of vertical eye motility; and (iii) distinguish patients experiencing vertical diplopia from healthy test subjects with ‘normal’ eye motility. Both recognition of patients’ experiences and prolonged follow-ups in selected cases are important for treatment feedback, and are prerequisites for improvement of future surgical outcomes. Current diagnostic methods appear to be insufficient. Vertical electro-oculography is suggested as a simple, objective and noninvasive eye motility test with the potential of helping predict which patients will benefit or not benefit from orbital floor surgery